Xiaowei Sun focuses her practice on complex intellectual property matters. Prior to joining WilmerHale, Dr. Sun was a patent analyst with IPSEN Bioscience, where she supported IP due diligence for acquisitions and licensing matters. She also conducted patentability and freedom-to-operate searches, built IP competitive landscapes to support research and development activities, prepared and drafted patent applications, and assisted with managing a global IP portfolio.

Dr. Sun was a postdoctoral fellow at Harvard Medical School and Boston Children’s Hospital. While there, Dr. Sun demonstrated the mechanism by which fructose promotes cancer, diabetes and fatty liver diseases. She was also awarded with a postdoctoral fellowship from the American Diabetes Association.

Dr. Sun was a PhD candidate at the Institut de Recherches Cliniques de Montreal, where she discovered the roles of a novel cholesterol lowering factor on liver cancer progression. She was previously a graduate student at Institut Pasteur, where she discovered a novel genetic alteration in fission yeast and obtained a research fellowship based on the findings.


  • Education

    • JD, Suffolk University Law School, 2021

      Staff Editor, Health and Biomedical Journal
    • PhD, Experimental Medicine, McGill University, 2013

    • MSc, Molecular Biology, University of Paris VI, 2006

    • BSc, Biochemistry, University of Paris VI, 2004

  • Admissions

    • Massachusetts

  • Languages

    • Chinese (Mandarin)

    • French



Unless you are an existing client, before communicating with WilmerHale by e-mail (or otherwise), please read the Disclaimer referenced by this link.(The Disclaimer is also accessible from the opening of this website). As noted therein, until you have received from us a written statement that we represent you in a particular manner (an "engagement letter") you should not send to us any confidential information about any such matter. After we have undertaken representation of you concerning a matter, you will be our client, and we may thereafter exchange confidential information freely.

Thank you for your interest in WilmerHale.